Shanghai Henlius Doses First Patient in Phase 1 Trial of PD-L1/VEGF Bispecific HLX37
I'm PortAI, I can summarize articles.
Shanghai Henlius Biotech, Inc. has initiated a first-in-human phase 1 clinical trial for HLX37, a bispecific antibody targeting PD-L1 and VEGF, in patients with advanced solid tumors. The trial will evaluate safety, tolerability, and efficacy, aiming to determine the maximum tolerated dose. HLX37 seeks to combine immune checkpoint blockade with anti-angiogenesis, potentially enhancing antitumor effects. The company is positioned to compete in the emerging market for PD-1/PD-L1 and VEGF bispecific antibodies. The latest analyst rating for Henlius stock is a Hold with a price target of HK$74.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments